Melatonin, widely recognized as the hormone regulating sleep-wake cycles, is gaining attention in obstetrics for its potential influence on labor processes, particularly during induction. Produced by the pineal gland, it peaks at night, coinciding with natural labor onsets, prompting research into its supplemental use to mimic physiological conditions in hospital-induced scenarios.
Understanding Melatonin in Pregnancy
During pregnancy, melatonin levels rise significantly, especially in the third trimester, supporting fetal development and maternal circadian rhythms. This hormone acts as a potent antioxidant, protecting cells from oxidative stress, which is crucial amid labor’s physical demands. Studies indicate melatonin’s presence in amniotic fluid and its role in synchronizing uterine activity with nocturnal patterns.
Its interaction with reproductive hormones like oxytocin is key. Laboratory evidence shows melatonin amplifies oxytocin-induced contractions in myometrial cells, potentially explaining why spontaneous labors often initiate overnight. In induced labor, typically conducted daytime, this natural surge is absent, leading researchers to investigate supplementation.
Why Consider Melatonin for Induced Labor?
Induction of labor (IOL) is increasingly common, used for post-term pregnancies, medical conditions, or maternal requests. However, it carries risks like prolonged labor, higher cesarean rates (up to 37% in some settings), and neonatal complications. Providing melatonin could bridge the gap between artificial induction and natural processes, enhancing uterine responsiveness and progression.
- Shorter labor duration: Potentially reduces time from induction to delivery.
- Higher vaginal birth rates: May decrease cesarean needs by improving contraction efficacy.
- Maternal comfort: Aligns with natural rhythms, possibly easing pain and fatigue.
Key Clinical Evidence on Melatonin Supplementation
Recent randomized controlled trials (RCTs) offer mixed yet intriguing data on melatonin’s efficacy in IOL.
A 2024 Australian double-blind RCT involving 189 women tested 10mg melatonin versus placebo during induction. While cesarean rates were similar (27.2% vs. 23.3%), the melatonin group showed lower spontaneous vaginal births within 24 hours (35% vs. 50%). Neonatal hypoglycemia risk was higher (18.5% vs. 8.1%), prompting caution.
Contrasting this, a 2023-2024 Egyptian RCT with 60 primigravid women found melatonin significantly improved outcomes: vaginal delivery rate rose to 86.7% from 60%, cesarean rates halved (23.3% vs. 46.7%), and induction-to-delivery interval shortened from 20 to 15.3 hours (p<0.001). All labor stages were briefer, with no adverse events reported.
| Study | Location/Year | Cesarean Rate (Melatonin vs Placebo) | Labor Duration Reduction | Neonatal Notes |
|---|---|---|---|---|
| Australian RCT | 2019-2021 | 27.2% vs 23.3% (no diff) | No significant change | Higher hypoglycemia risk |
| Egyptian RCT | 2023-2024 | 23.3% vs 46.7% (p=0.03) | Significant (15.3 vs 20 hrs) | No adverse events |
These discrepancies may stem from sample size, population differences (primigravidas vs mixed parity), dosing protocols, or regional practices. The Australian trial ended early due to COVID-19 logistics, potentially underpowering results.
Biological Mechanisms at Play
Melatonin’s labor-promoting effects likely involve multiple pathways. It enhances oxytocin sensitivity in uterine smooth muscle, boosting IP3 signaling and contraction strength in vitro. Animal models and human studies link rising melatonin to increased myometrial contractility near term.
As an antioxidant, it mitigates oxidative stress from prolonged inductions, protecting both mother and fetus. Sublingual or oral forms achieve rapid bioavailability, mimicking nocturnal peaks during daytime procedures.
Potential Benefits for Mothers and Babies
Maternal Advantages
- Reduced cesarean risk: Positive trials show up to 50% drop, sparing surgical recovery.
- Faster progression: Shorter first, second, and third stages minimize exhaustion and intervention needs.
- Lower hemorrhage: One study noted trends toward less postpartum blood loss, though not always significant.
Neonatal Outcomes
Most data affirm safety, with strong APGAR scores and no major complications in favorable trials. However, monitoring for hypoglycemia is advised, especially in protocols like the Australian study.
Safety Profile and Side Effects
Melatonin is generally safe in pregnancy, classified as low-risk by experts. Doses of 10mg intrapartum show minimal maternal side effects like drowsiness. Neonatal concerns are rare but include transient hypoglycemia, possibly from metabolic shifts.
No links to birth defects or long-term issues; its endogenous production supports physiologic use. Always consult providers, as interactions with induction agents like prostaglandins or oxytocin require oversight.
Practical Considerations for Use
Dosing: Trials used 10mg oral or sublingual at induction start, repeated up to 4 times over 6-24 hours.
Timing: Best at cervical ripening onset to align with labor augmentation.
Who benefits most? Primigravidas or those with unfavorable cervixes may see greatest gains, per Egyptian data.
Integration into protocols awaits larger trials, but off-label use is emerging in supportive settings.
Expert Perspectives and Ongoing Research
Obstetricians view melatonin as promising for optimizing IOL, potentially cutting healthcare costs via fewer cesareans. Gaps persist: optimal dosing, long-term follow-up, and diverse populations need exploration. Future studies may clarify subgroup benefits, like parity or induction method.
Frequently Asked Questions
Is melatonin safe during induced labor?
Yes, clinical trials report it as safe at 10mg doses, with minor side effects. Monitor neonates for hypoglycemia.
Does melatonin guarantee a vaginal birth?
No, but some studies show higher success rates (up to 86.7%). Results vary by trial.
How quickly does it work?
Effects on contractions appear within hours, shortening overall labor by 4-5 hours in positive studies.
Can I take melatonin without a doctor?
No, only under medical supervision during induction to ensure proper dosing and monitoring.
What if I’m already in labor?
Primarily studied for induction; consult for spontaneous labor use.
References
- A double-blind, randomized, placebo-controlled trial of melatonin as an adjunct to induction of labour (MELB) — Acta Obstetricia et Gynecologica Scandinavica. 2024-10-15. https://pubmed.ncbi.nlm.nih.gov/39446608/
- Evaluation of Melatonin Effect on Induction of Labor — Egyptian Journal of Fertility Studies. 2024. https://egyfs.journals.ekb.eg/article_441440_1779d7eb9edc4ab85332e6ff92c3ad70.pdf
- A double-blind randomised placebo-controlled trial of melatonin as an adjunct to induction of labour — PMC. 2020-02-20. https://pmc.ncbi.nlm.nih.gov/articles/PMC7044825/
- Melatonin and Female Reproduction: An Expanding Universe — Frontiers in Endocrinology. 2020-03-04. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2020.00085/full
- A double‐blind, randomized, placebo‐controlled trial of melatonin as an adjunct to induction of labour — Acta Obstetricia et Gynecologica Scandinavica. 2024. https://obgyn.onlinelibrary.wiley.com/doi/10.1111/aogs.14951
